產(chǎn)品名稱 |
CEM-CM3 |
商品貨號(hào) |
B164228 |
Organism |
Homo sapiens, human |
Tissue |
peripheral blood |
Cell Type |
T lymphoblast |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
acute lymphoblastic leukemia |
Age |
4 years |
Gender |
female |
Ethnicity |
Caucasian |
Applications |
This line was derived from CCRF-CEM (see ATCC CCL-119) by selecting for resistance to 8-azaguanine. The line has been used as a fusion partner in the production of human-human T cell hybridomas. |
Storage Conditions |
liquid nitogen vapor phase |
Derivation |
This line was derived from CCRF-CEM (see ATCC CCL-119) by selecting for resistance to 8-azaguanine. |
Clinical Data |
female Caucasian 4 years |
Comments |
This line was derived from CCRF-CEM (see ATCC CCL-119) by selecting for resistance to 8-azaguanine. The line has been used as a fusion partner in the production of human-human T cell hybridomas. |
Complete Growth Medium |
RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.015 mg/ml 8-azaguanine, 90%; fetal bovine serum, 10%
|
Subculturing |
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 1 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml. Medium Renewal: Every 2 to 3 days |
Cryopreservation |
Freeze medium: culture medium 95%; DMSO, 5% Storage temperature: liquid nitogen vapor phase |
Culture Conditions |
Temperature: 37.0°C |
STR Profile |
Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 10,12 D5S818: 12,13 D7S820: 10,13 THO1: 6,7 TPOX: 8 vWA: 18,19 |
Name of Depositor |
MK Cathcart |
Deposited As |
Homo sapiens |
References |
Cathcart MK, Murakami MNonspecific suppression of antibody synthesis by products of human T lymphocyte hybridomas. Use of a newly selected parent fusion lineIn: Cathcart MK, Murakami MT cell hybridomasBoca Raton, FLCRC Presspp. 227-236, 1985
. Human T lymphocyte hybridomas: production of nonspecific suppressor factors of antibody synthesis. Kyoto, Japan: 5th International Congress of Immunology; 1983.
. . Clin. Res. 31: 734A, 1983.
|